Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Introduction: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Some patients treated with phosphodiesterase type 5 inhibitors (PDE-5is) fail to reach treatment goals. As a novel soluble guanylate cyclase agonist, riociguat acts on the same pathway as PDE-5is but functions via...

Full description

Bibliographic Details
Main Authors: Yu-Yang Liu, Yi-Yang Qu, Shang Wang, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Ping Yuan, Lan Wang, Jin-Ling Li, Rong Jiang, Rui Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
pulmonary arterial hypertension
riociguat
systematic review
meta
analysis
phosphodiesterase-5 inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1052546/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1052546/full

Similar Items